Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 23812092)

1.

Anti-cyclic citrullinated peptide antibodies do not reflect self-reported disability and physical health in patients with rheumatoid arthritis of less than 5 years of duration.

Poulsen CH, Jacobsen S, Frisch M, Frederiksen K, Johansen C.

Rheumatol Int. 2013 Nov;33(11):2763-72. doi: 10.1007/s00296-013-2807-z. Epub 2013 Jun 29.

PMID:
23812092
2.

Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan.

Shidara K, Inoue E, Hoshi D, Sato E, Nakajima A, Momohara S, Taniguchi A, Yamanaka H.

Rheumatol Int. 2012 Feb;32(2):361-6. doi: 10.1007/s00296-010-1671-3. Epub 2010 Nov 27.

PMID:
21113712
3.

[The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].

Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M.

Mikrobiyol Bul. 2008 Oct;42(4):669-74. Turkish.

PMID:
19149089
4.

Disability and quality-of-life are not influenced by the prevalence of autoantibodies in early rheumatoid arthritis patients--results of the Brasília Cohort.

Mota LM, Santos Neto LL, Burlingame RW, Ménard HA, Pereira IA, Carvalho JF, Laurindo IM.

Rev Bras Reumatol. 2012 Dec;52(6):824-9. English, Portuguese.

5.

Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis.

Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Rönnelid J, Rantapää-Dahlqvist S.

Arthritis Res Ther. 2011 Feb 3;13(1):R13. doi: 10.1186/ar3237.

6.

Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.

Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, Inanc M.

Clin Rheumatol. 2007 Jan;26(1):17-23. Epub 2006 Mar 15.

PMID:
16538391
7.

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.

van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW.

Arthritis Res Ther. 2005;7(5):R949-58. Epub 2005 Jun 14.

8.
9.

Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides.

Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, Frisch M.

Arthritis Res Ther. 2006;8(4):R133.

10.

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.

van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.

Arthritis Rheum. 2009 Aug;60(8):2232-41. doi: 10.1002/art.24716.

11.

Role of anti cyclic citrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis.

Shankar S, Grover R, Handa R.

Indian J Med Res. 2006 Dec;124(6):689-96.

PMID:
17287557
12.

Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families.

Kim SK, Bae J, Lee H, Kim JH, Park SH, Choe JY.

Korean J Intern Med. 2013 Jan;28(1):45-53. doi: 10.3904/kjim.2013.28.1.45. Epub 2012 Dec 28.

13.

Cartilage oligomeric matrix protein associates differentially with erosions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus anti-CCP-negative early rheumatoid arthritis.

Christensen AF, Lindegaard H, Hørslev-Petersen K, Hetland ML, Ejbjerg B, Stengaard-Pedersen K, Jacobsen S, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, Pødenphant J, Østergaard M, Junker P.

J Rheumatol. 2011 Aug;38(8):1563-8. doi: 10.3899/jrheum.101241. Epub 2011 May 15.

14.

Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies.

Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP.

Arthritis Care Res (Hoboken). 2010 May;62(5):664-75. doi: 10.1002/acr.20207.

15.

Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.

Lim MK, Sheen DH, Lee YJ, Mun YR, Park M, Shim SC.

J Rheumatol. 2009 Apr;36(4):712-6. doi: 10.3899/jrheum.080653. Epub 2009 Mar 13.

PMID:
19286846
16.

Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark.

Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, Svejgaard A, Pedersen BV, Wohlfahrt J, Frisch M.

Arthritis Rheum. 2007 May;56(5):1446-53.

17.
18.

Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.

Keskin G, Inal A, Keskin D, Pekel A, Baysal O, Dizer U, Sengül A.

Protein Pept Lett. 2008;15(3):314-7.

PMID:
18336364
19.

Differential association of HLA-DRB1 alleles in Japanese patients with early rheumatoid arthritis in relationship to autoantibodies to cyclic citrullinated peptide.

Furuya T, Hakoda M, Ichikawa N, Higami K, Nanke Y, Yago T, Kobashigawa T, Tokunaga K, Tsuchiya N, Kamatani N, Kotake S.

Clin Exp Rheumatol. 2007 Mar-Apr;25(2):219-24.

PMID:
17543145
20.

Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis.

Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, Montgomery DS, Binks MH, Wilson AG.

Arthritis Res Ther. 2006;8(4):R128.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk